Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | SAMETA: Phase III trial of durvalumab and savolitinib in aPRC

Francesca Jackson-Spence • 15 Feb 2025
GU Cancers 2025
Genitourinary Cancer Kidney Cancer Antibodies Checkpoint Inhibitors Durvalumab Savolitinib
SAMETA

Francesca Jackson-Spence, MBChB, Barts Cancer Centre, London, UK, provides an overview of the Phase III SAMETA trial (NCT03091192), a randomized study evaluating the combination of savolitinib and durvalumab in patients with advanced papillary renal cell carcinoma. Enrollment has completed and the results of this trial are anticipated. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francesca Jackson-Spence

What role will MET inhibitors have in managing papillary renal cancer?
0:32
What role will MET inhibitors have in managing papillary renal cancer?
Francesca Jackson-Spence • 15 Feb 2025
CALYPSO: final OS and ctDNA findings of durvalumab and savolitinib in aPRC
2:08
CALYPSO: final OS and ctDNA findings of durvalumab and savolitinib in aPRC
Francesca Jackson-Spence • 15 Feb 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals